Jump to Main Content
Discovery and horizontal follow-up of an autoantibody signature in human prostate cancer
- Mintz, Paul J., Rietz, Anna Cecilia, Cardó-Vila, Marina, Ozawa, Michael G., Dondossola, Eleonora, Do, Kim-Anh, Kim, Jeri, Troncoso, Patricia, Logothetis, Christopher J., Sidman, Richard L., Pasqualini, Renata, Arap, Wadih
- Proceedings of the National Academy of Sciences of the United States of America 2015 v.112 no.8 pp. 2515-2520
- autoantibodies, biomarkers, blood serum, glycoproteins, humans, metastasis, patients, prostatic neoplasms, risk
- Significance For the management of prostate cancer it has remained a significant clinical challenge to identify biomarkers that can be used as prognostic indicators to facilitate early treatment decisions and indicate patients at risk for castrate-resistant bone-metastatic prostate cancer in need of more aggressive treatment. In this report, serum antibodies to alpha-2–Heremans–Schmidt glycoprotein (fetuin-A) were demonstrated to display increased reactivity with concomitant development of metastatic castrate-resistant disease in a large cohort of prostate cancer patients. Furthermore, metastatic prostate cancer cell lines and bone metastasis samples displayed robust fetuin-A expression. To our knowledge, this is the first report to indicate that serum autoantibodies reactive to fetuin-A show utility as a prognostic indicator for prostate cancer patients at risk for progressing to metastatic disease.